Αποτελέσματα Αναζήτησης
27 Μαΐ 2023 · Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An Age-Period-Cohort...
- Metrics
We would like to show you a description here but the site...
- Full Size Image
We would like to show you a description here but the site...
- Metrics
The study by Wang et al investigating 16025 male and 1,800,708 female patients diagnosed with breast cancer from the National Cancer Data Base (NCDB) between 2004 and 2014 demonstrated that overall mortality and mortality at three and five years are higher in men when compared to women even after adjusting for clinical characteristics ...
1 Νοε 2021 · Results: In 2015-2017, Central-Eastern Europe had a rate of 2.85/1 000 000, and Russia of 2.22, ranking among the highest. North-Western and Southern Europe, the European Union as a whole and the USA showed rates ranging between 1.5 and 2.0.
13 Απρ 2020 · Among men with a personal history of breast cancer, 27.8% (5/18) tested positive for breast cancer–related mutations, including BRCA2 (n = 3), NBN (n = 1), and BARD (n = 1) mutations. Most BRCA mutation carriers (80.9%, 51/63) were recommended CBE only.
CANCER TODAY enables a comprehensive assessment of the cancer burden worldwide in 2022, based on the GLOBOCAN estimates of incidence, mortality and prevalence for year 2022 in 185 countries or territories for 36 cancer types by sex and age group.
14 Φεβ 2020 · What is the optimal management for men with breast cancer including use of adjuvant endocrine therapy, use of endocrine therapy for advanced or metastatic disease, targeted therapies, management of treatment-related adverse effects, genetic testing, and post-treatment surveillance? Target Population. Men diagnosed with invasive breast cancer.
This article reviews male breast cancer demographics, risk factors, tumor biology, and oncogenetics; recognizes how male breast cancer differs from its female counterpart; highlights its diagnostic challenges; discusses the implications of the widening clinical use of multigene panel testing; outlines current National Comprehensive Cancer ...
